PharmaCorp Rx (PCRX.V) on Tuesday closed a bought-deal public offering for gross proceeds of C$11.5 million, including the full exercise of the underwriters' over-allotment option.
Underwriters purchased 22.55-million units priced at C$0.51 and made up of a share and one half of a two-year warrant to buy a share for C$0.60.
Proceeds will be used for future acquisition opportunities and general working capital requirements, the company said.
The company's shares were last seen unchanged at C$0.50 on the TSX Venture Exchange.